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Background: We previously demonstrated that a biodegradable polymer drug-eluting stent (DES) was non-inferior to permanent polymer DES in 
the ISAR-TEST-4 randomized trial, a study powered for clinical endpoints. In the current analysis we compare the antirestenotic efficacy of these 
stents at 6-8-month angiographic follow up.
Methods: Patients with de novo coronary lesions in native vessels were randomly assigned to receive a biodegradable polymer (BP) sirolimus-
eluting stent or a permanent polymer (PP) sirolimus/everolimus eluting stent. In this analysis we focused on 2 major angiographic enpoints of 
interest: in-stent late lumen loss and in-segment binary restenosis at 6-8- month follow-up angiogram.
Results: Of a total of 2603 patients (3372 lesions): 1299 patients (1683 lesions) received BP stents, 1304 patients (1689 lesions) were treated 
with PP stents. Repeat angiography was available for 2637 lesions (78.2%). Mean late lumen loss was 0.24 ± 0.54 mm in the BP stent group, 0.26 ± 
0.57 mm in the PP group (p=0.49). In-segment binary restenosis occurred in 153 lesions (11.6%) in the BP group and 155 lesions (11.8%) in the PP 
Group (p=0.85). The BP stent group showed similar rates of target vessel revascularization 170 (13.7%) in the BP and 172 (13.9%) in the PP Group, 
(p= 0.83).
Conclusions: This analysis showes that the antirestenotic performance of the BP stent is compareable to that of the PP stent.
